Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE) is a global biopharmaceutical leader driving innovations in vaccine development and therapeutic treatments. This news hub provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and market strategies.
Access official press releases, earnings reports, and analysis of Pfizer's clinical trial progress. Our curated collection covers FDA approvals, partnership announcements, and research breakthroughs across oncology, immunology, and infectious disease portfolios.
Key updates include quarterly financial results, manufacturing expansions, and strategic collaborations shaping the pharmaceutical landscape. Bookmark this page for reliable insights into one of healthcare's most influential companies, with content organized for efficient navigation across devices.
Pfizer's Phase 3 ECHELON-3 study on ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed significant results. The regimen reduced the risk of death by 37% compared to chemotherapy alone, with a median overall survival of 13.8 months versus 8.5 months. The study included 230 patients and will be presented at the 2024 ASCO Annual Meeting. ADCETRIS demonstrated consistent benefits across different levels of CD30 expression and is a standard of care in several lymphomas. Median progression-free survival was 4.2 months for the ADCETRIS regimen compared to 2.6 months for the placebo group. The overall response rate was 64.3% versus 41.5%, and complete response rate was 40.2% versus 18.6%. Adverse events included higher rates of neutropenia, thrombocytopenia, and anemia in the ADCETRIS group.
Pfizer's Phase 3 CROWN trial results showed that 60% of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) treated with LORBRENA (lorlatinib) lived beyond five years without disease progression. These results represent an 81% reduction in risk of progression or death compared to XALKORI (crizotinib). The study also reported a 94% reduction in brain metastasis progression. LORBRENA demonstrated consistent safety profiles, with no new safety signals reported. The findings were presented at the 2024 ASCO Annual Meeting and published in the Journal of Clinical Oncology.
Astellas Pharma Inc. will present new research at the 2024 ASCO Annual Meeting showcasing scientific advancements in its oncology portfolio. The company will share data from pivotal trials across various hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction cancers. Key highlights include Phase 3 trial data supporting enfortumab vedotin, final overall survival results from the SPOTLIGHT study on zolbetuximab, and post-hoc analyses of the EMBARK trial on enzalutamide. Astellas continues to focus on innovative therapies for cancer patients.
Pfizer announced that Andrew Baum, M.D., will join as Chief Strategy and Innovation Officer, EVP. Dr. Baum brings extensive experience in healthcare, equity research, and global partnerships. He will lead Pfizer's strategic plan, portfolio analysis, and business development activities. Dr. Baum will also chair Pfizer's Portfolio Management Team, focusing on advancing vaccines and medicines.
Pfizer Inc. (NYSE: PFE) reported Q1 2024 revenues of $14.9 billion, an operational decrease of 19%. Adjusted diluted EPS was $0.82, reflecting a $0.11 favorable impact. The company raised its Adjusted EPS guidance to $2.15-$2.35 and reaffirmed its 2024 revenue guidance of $58.5-$61.5 billion. Pfizer continues to focus on commercial execution and cost savings, with strong performance in non-COVID products.
The FDA has granted full approval for TIVDAK® for the treatment of recurrent or metastatic cervical cancer. TIVDAK is the first antibody-drug conjugate with positive overall survival data for patients with previously treated disease. The approval is based on results from a Phase 3 study showing an overall survival benefit compared to chemotherapy. The safety profile of TIVDAK was consistent with known information, with no new safety issues identified. Common adverse reactions included decreased hemoglobin, peripheral neuropathy, and conjunctival adverse reactions. The approval of TIVDAK brings new treatment options for patients with advanced cervical cancer and addresses the high unmet need in this patient population.
Genmab A/S and Pfizer Inc. announced that the U.S. FDA has approved TIVDAK® for recurrent or metastatic cervical cancer treatment, converting its accelerated approval to a full approval. This is the first ADC with positive overall survival data in this patient population. The approval is based on Phase 3 data showing a 30% risk reduction in death compared to chemotherapy.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
